AR102258A1 - QUINOLINE AND QUINAZOLINE COMPOUNDS - Google Patents
QUINOLINE AND QUINAZOLINE COMPOUNDSInfo
- Publication number
- AR102258A1 AR102258A1 ARP150103310A ARP150103310A AR102258A1 AR 102258 A1 AR102258 A1 AR 102258A1 AR P150103310 A ARP150103310 A AR P150103310A AR P150103310 A ARP150103310 A AR P150103310A AR 102258 A1 AR102258 A1 AR 102258A1
- Authority
- AR
- Argentina
- Prior art keywords
- alkyl
- optionally substituted
- alkoxy
- amino
- heterocycloalkyl
- Prior art date
Links
- SMWDFEZZVXVKRB-UHFFFAOYSA-N Quinoline Chemical compound N1=CC=CC2=CC=CC=C21 SMWDFEZZVXVKRB-UHFFFAOYSA-N 0.000 title 2
- JWVCLYRUEFBMGU-UHFFFAOYSA-N quinazoline Chemical class N1=CN=CC2=CC=CC=C21 JWVCLYRUEFBMGU-UHFFFAOYSA-N 0.000 title 1
- 125000004178 (C1-C4) alkyl group Chemical group 0.000 abstract 13
- 229910052736 halogen Inorganic materials 0.000 abstract 8
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 abstract 8
- 150000002367 halogens Chemical class 0.000 abstract 7
- 125000002887 hydroxy group Chemical group [H]O* 0.000 abstract 7
- 125000006274 (C1-C3)alkoxy group Chemical group 0.000 abstract 6
- 125000000592 heterocycloalkyl group Chemical group 0.000 abstract 6
- 229910052760 oxygen Inorganic materials 0.000 abstract 5
- 229910052717 sulfur Inorganic materials 0.000 abstract 5
- 125000006273 (C1-C3) alkyl group Chemical group 0.000 abstract 4
- 125000000041 C6-C10 aryl group Chemical group 0.000 abstract 4
- 125000004093 cyano group Chemical group *C#N 0.000 abstract 4
- 125000000000 cycloalkoxy group Chemical group 0.000 abstract 4
- 125000006272 (C3-C7) cycloalkyl group Chemical group 0.000 abstract 3
- 125000000882 C2-C6 alkenyl group Chemical group 0.000 abstract 3
- 125000003601 C2-C6 alkynyl group Chemical group 0.000 abstract 3
- 125000004429 atom Chemical group 0.000 abstract 3
- 125000001072 heteroaryl group Chemical group 0.000 abstract 3
- 125000004169 (C1-C6) alkyl group Chemical group 0.000 abstract 2
- 125000003545 alkoxy group Chemical group 0.000 abstract 2
- 125000000217 alkyl group Chemical group 0.000 abstract 2
- 125000006656 (C2-C4) alkenyl group Chemical group 0.000 abstract 1
- 125000006650 (C2-C4) alkynyl group Chemical group 0.000 abstract 1
- 125000005913 (C3-C6) cycloalkyl group Chemical group 0.000 abstract 1
- -1 C3− cycloalkyl 7 Chemical group 0.000 abstract 1
- 102220517591 Methyl-CpG-binding domain protein 3-like 2B_R11C_mutation Human genes 0.000 abstract 1
- 125000003342 alkenyl group Chemical group 0.000 abstract 1
- 125000000304 alkynyl group Chemical group 0.000 abstract 1
- 150000001875 compounds Chemical class 0.000 abstract 1
- 125000000392 cycloalkenyl group Chemical group 0.000 abstract 1
- 125000005843 halogen group Chemical group 0.000 abstract 1
- 125000005842 heteroatom Chemical group 0.000 abstract 1
- 125000004366 heterocycloalkenyl group Chemical group 0.000 abstract 1
- 102200080066 rs122460151 Human genes 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
Abstract
Reivindicación 1: Un compuesto de la fórmula (1) o una sal farmacéuticamente aceptable del mismo, en donde: A es CH o N, con la condición de que si B es N, A sea CH; B es CH o N, con la condición de que si A es N, B sea CH; T es CH o N; U es CH o N; V es NR⁵, O, S, SO o SO₂; W es CH, N, O ó S; X es C(R⁶), N, O ó S; Y es CH, N o enlace; Z es CH o N; con la condición de que: 0 a 2 átomos de W, X, Y puedan ser simultáneamente un heteroátomo; cuando un átomo seleccionado de entre W, X, Y es O ó S, entonces otro átomo seleccionado entre W, X, Y no puede ser O ó S; cuando Y es CH o N, entonces X es C(R⁶) o N y W es CH o N; R¹ es H, alquilo C₁₋₄ opcionalmente sustituido con R⁷ o C(O)R⁷, o alcoxi C₁₋₅ opcionalmente sustituido con R⁷ o C(O)R⁷, u O-heterocicloalquilo C₂₋₆ opcionalmente sustituido con hidroxilo o alquilo C₁₋₄; R³ es H, alquilo C₁₋₃ opcionalmente sustituido con R⁷, o cicloalquilo C₃₋₇ opcionalmente sustituido con R⁷; R⁴ es H, R¹¹C(O), R¹²S(O), R¹³SO₂, o alquilo C₁₋₆ opcionalmente sustituido con R¹⁴; R¹ y R³ juntos pueden formar un heterocicloalquilo C₂₋₆; R⁵ es H o alquilo C₁₋₃; R² es H, halógeno, ciano, alquilo C₁₋₄, alquenilo C₂₋₄, alquinilo C₂₋₄, alcoxi C₁₋₃, cicloalquilo C₃₋₆; todos los grupos alquilo de R² están opcionalmente sustituidos con uno o más halógenos; o R² es arilo C₆₋₁₀ o heterocicloalquilo C₂₋₆; R⁶ es H o alquilo C₁₋₃; o R² y R⁶ juntos pueden formar un cicloalquenilo C₃₋₇, o heterocicloalquenilo C₂₋₆; cada uno opcionalmente sustituido con alquilo C₁₋₃, o uno o más halógenos; R⁷ es H, alcoxi C₁₋₃, o un heterocicloalquilo C₂₋₆; (uno o más) hidroxilo, [alquilo C₁₋₄]amino, di[alquilo C₁₋₄]amino, cicloalcoxi C₃₋₇; R¹¹ se selecciona independientemente del grupo que consiste en alquilo C₁₋₆, alquenilo C₂₋₆ y alquinilo C₂₋₆ donde cada alquilo, alquenilo o alquinilo está opcionalmente sustituido con uno o más grupos seleccionados entre hidroxilo, alquilo C₁₋₄, cicloalquilo C₃₋₇, alcoxi C₁₋₃, cicloalcoxi C₃₋₇, [alquilo C₁₋₄]amino opcionalmente sustituido con hidroxilo, halógeno, o alcoxi C₁₋₃, di[alquilo C₁₋₄]amino opcionalmente sustituido con hidroxilo, halógeno, o alcoxi C₁₋₃, arilo C₆₋₁₀ o heterocicloalquilo C₃₋₇, o R¹¹ es heteroarilo C₁₋₅ opcionalmente sustituido con uno o más grupos seleccionados de halógeno o ciano; R¹² y R¹³ se seleccionan independientemente entre el grupo constituido por alquenilo C₂₋₆ o alquinilo C₂₋₆ ambos opcionalmente sustituidos con uno o más grupos seleccionados de hidroxilo, alquilo C₁₋₄, cicloalquilo C₃₋₇, [alquilo C₁₋₄]amino, di[alquilo C₁₋₄]amino, alcoxi C₁₋₃, cicloalcoxi C₃₋₇, arilo C₆₋₁₀, o heterocicloalquilo C₃₋₇; o heteroarilo C₁₋₅ opcionalmente sustituido con uno o más grupos seleccionados de halógeno o ciano; R¹⁴ se selecciona independientemente del grupo que consiste en halógeno, ciano o alquenilo C₂₋₆ o alquinilo C₂₋₆ ambos opcionalmente sustituidos con uno o más grupos seleccionados entre hidroxilo, alquilo C₁₋₄, cicloalquilo C₃₋₇, [alquilo C₁₋₄]amino, di[alquilo C₁₋₄]amino, alcoxi C₁₋₃, cicloalcoxi C₃₋₇, arilo C₆₋₁₀, heteroarilo C₁₋₅ o heterocicloalquilo C₃₋₇.Claim 1: A compound of the formula (1) or a pharmaceutically acceptable salt thereof, wherein: A is CH or N, provided that if B is N, A is CH; B is CH or N, with the proviso that if A is N, B is CH; T is CH or N; U is CH or N; V is NR⁵, O, S, SO or SO₂; W is CH, N, O or S; X is C (R⁶), N, O or S; Y is CH, N or link; Z is CH or N; with the proviso that: 0 to 2 atoms of W, X, Y can simultaneously be a heteroatom; when an atom selected from W, X, Y is O or S, then another atom selected from W, X, Y cannot be O or S; when Y is CH or N, then X is C (R⁶) or N and W is CH or N; R¹ is H, C₁₋₄ alkyl optionally substituted with R⁷ or C (O) R⁷, or C₁₋₅ alkoxy optionally substituted with R⁷ or C (O) R⁷, or C₂₋₆ O-heterocycloalkyl optionally substituted with hydroxyl or C₁₋ alkyl ₄; R³ is H, C₁₋₃ alkyl optionally substituted with R⁷, or C₃₋₇ cycloalkyl optionally substituted with R⁷; R⁴ is H, R¹¹C (O), R¹²S (O), R¹³SO₂, or C₁₋₆ alkyl optionally substituted with R¹⁴; R¹ and R³ together can form a C₂₋₆ heterocycloalkyl; R⁵ is H or C₁₋₃ alkyl; R² is H, halogen, cyano, C₁₋₄ alkyl, C₂₋₄ alkenyl, C₂₋₄ alkynyl, C₁₋₃ alkoxy, C₃₋₆ cycloalkyl; all R² alkyl groups are optionally substituted with one or more halogens; or R² is C₆₋₁₀ aryl or C₂₋₆ heterocycloalkyl; R⁶ is H or C₁₋₃ alkyl; or R² and R⁶ together can form a C₃₋₇ cycloalkenyl, or C₂₋₆ heterocycloalkenyl; each optionally substituted with C₁₋₃ alkyl, or one or more halogens; R⁷ is H, C₁₋₃ alkoxy, or a C₂₋₆ heterocycloalkyl; (one or more) hydroxyl, [C₁₋₄ alkyl] amino, di [C₁₋₄ alkyl] amino, C₃₋₇ cycloalkoxy; R¹¹ is independently selected from the group consisting of C₁₋₆ alkyl, C₂₋₆ alkenyl and C₂₋₆ alkynyl where each alkyl, alkenyl or alkynyl is optionally substituted with one or more groups selected from hydroxyl, C₁₋₄ alkyl, C₃₋ cycloalkyl ₇, C₁₋₃ alkoxy, C₃₋₇ cycloalkoxy, [C₁₋₄ alkyl] amino optionally substituted with hydroxyl, halogen, or C₁₋₃ alkoxy, di [C₁₋₄ alkyl] amino optionally substituted with hydroxyl, halogen, or C₁ alkoxy ₋₃, C₆₋₁₀ aryl or C₃₋₇ heterocycloalkyl, or R¹¹ is C₁₋₅ heteroaryl optionally substituted with one or more groups selected from halogen or cyano; R¹² and R¹³ are independently selected from the group consisting of C₂₋₆ alkenyl or C₂₋₆ alkynyl both optionally substituted with one or more groups selected from hydroxyl, C₁₋₄ alkyl, C₃₋₇ cycloalkyl, [C₁₋₄ alkyl] amino, di [C₁₋₄ alkyl] amino, C₁₋₃ alkoxy, C₃₋₇ cycloalkoxy, C₆₋₁₀ aryl, or C₃₋₇ heterocycloalkyl; or C₁₋₅ heteroaryl optionally substituted with one or more groups selected from halogen or cyano; R¹⁴ is independently selected from the group consisting of halogen, cyano or C₂₋₆ alkenyl or C₂₋₆ alkynyl both optionally substituted with one or more groups selected from hydroxyl, C₁₋₄ alkyl, C₃₋₇ cycloalkyl, [C₁₋₄ alkyl] amino, di [C₁₋₄ alkyl] amino, C₁₋₃ alkoxy, C₃₋₇ cycloalkoxy, C₆₋₁₀ aryl, C₁₋₅ heteroaryl or C₃₋₇ heterocycloalkyl.
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201462062823P | 2014-10-10 | 2014-10-10 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AR102258A1 true AR102258A1 (en) | 2017-02-15 |
Family
ID=54330822
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ARP150103310A AR102258A1 (en) | 2014-10-10 | 2015-10-13 | QUINOLINE AND QUINAZOLINE COMPOUNDS |
Country Status (3)
| Country | Link |
|---|---|
| AR (1) | AR102258A1 (en) |
| TW (1) | TW201629036A (en) |
| WO (1) | WO2016055982A1 (en) |
Families Citing this family (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP3079683A4 (en) | 2013-12-13 | 2017-12-20 | Dana-Farber Cancer Institute, Inc. | Methods to treat lymphoplasmacytic lymphoma |
| JP6325760B1 (en) | 2015-05-29 | 2018-05-16 | エーザイ・アール・アンド・ディー・マネジメント株式会社 | Tetrasubstituted alkene compounds and uses thereof |
| WO2018026877A1 (en) | 2016-08-05 | 2018-02-08 | Calitor Sciences, Llc | Process for preparing substituted quinolin-4-ol compounds |
| IL266003B (en) * | 2016-11-28 | 2022-08-01 | Eisai R&D Man Co Ltd | Salts of indazole derivatives and their crystals |
| MX2021003517A (en) | 2018-09-25 | 2021-08-16 | Black Diamond Therapeutics Inc | Quinazoline derivatives as tyrosine kinase inhibitor, compositions, methods of making them and their use. |
| MX2022001467A (en) * | 2019-08-08 | 2022-05-06 | B C I Pharma | QUINOLINE DERIVATIVES AS PROTEIN KINASE INHIBITORS. |
| AU2020328598A1 (en) | 2019-08-15 | 2022-03-03 | Black Diamond Therapeutics, Inc. | Alkynyl quinazoline compounds |
| US20230339865A1 (en) * | 2020-06-05 | 2023-10-26 | Dana-Farber Cancer Institute, Inc. | Quinazoline-derived hck inhibitors for use in the treatment of myd88 mutated diseases |
| CN115197135B (en) * | 2022-08-30 | 2023-09-19 | 鲁东大学 | A zinc-catalyzed method for preparing multi-substituted quinoline compounds |
| WO2025151487A2 (en) * | 2024-01-08 | 2025-07-17 | Regents Of The University Of Michigan | Small-molecule inhibitors of adar1 |
Family Cites Families (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5023252A (en) | 1985-12-04 | 1991-06-11 | Conrex Pharmaceutical Corporation | Transdermal and trans-membrane delivery of drugs |
| US5001139A (en) | 1987-06-12 | 1991-03-19 | American Cyanamid Company | Enchancers for the transdermal flux of nivadipine |
| US4992445A (en) | 1987-06-12 | 1991-02-12 | American Cyanamid Co. | Transdermal delivery of pharmaceuticals |
| JPH0565233A (en) | 1991-03-08 | 1993-03-19 | Mitsui Toatsu Chem Inc | Monoclonal antibody-containing lyophilized preparation |
| US6267958B1 (en) | 1995-07-27 | 2001-07-31 | Genentech, Inc. | Protein formulation |
| CA2454587C (en) | 2001-07-25 | 2012-11-13 | Protein Design Labs, Inc. | Stable lyophilized pharmaceutical formulation of igg antibodies |
| AU2007260769A1 (en) | 2006-06-14 | 2007-12-21 | Imclone Llc | Lyophilized formulations of anti-EGFR antibodies |
| US7894450B2 (en) | 2007-12-31 | 2011-02-22 | Nortel Network, Ltd. | Implementation of VPNs over a link state protocol controlled ethernet network |
| US8193182B2 (en) | 2008-01-04 | 2012-06-05 | Intellikine, Inc. | Substituted isoquinolin-1(2H)-ones, and methods of use thereof |
| EP2240451B1 (en) | 2008-01-04 | 2017-08-09 | Intellikine, LLC | Isoquinolinone derivatives substituted with a purine useful as PI3K inhibitors |
| CA2726460C (en) * | 2008-07-15 | 2017-02-21 | F. Hoffmann-La Roche Ag | Novel phenyl-imidazopyridines and pyridazines |
| CA2841886C (en) * | 2011-07-19 | 2016-08-16 | Merck Sharp & Dohme B.V. | 4-imidazopyridazin-1-yl-benzamides and 4-imidazotriazin-1-yl-benzamides as btk-inhibitors |
-
2015
- 2015-10-09 WO PCT/IB2015/057746 patent/WO2016055982A1/en not_active Ceased
- 2015-10-12 TW TW104133386A patent/TW201629036A/en unknown
- 2015-10-13 AR ARP150103310A patent/AR102258A1/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| WO2016055982A1 (en) | 2016-04-14 |
| TW201629036A (en) | 2016-08-16 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AR102258A1 (en) | QUINOLINE AND QUINAZOLINE COMPOUNDS | |
| AR110405A1 (en) | COMPOUNDS | |
| CL2018003504A1 (en) | Substituted carbonucleoside derivatives useful as antineoplastic agents. | |
| AR103561A1 (en) | HERBICIDE Phenylpyridines | |
| AR106301A1 (en) | PIRROLPIRIMIDINE COMPOSITIONS AS KINASE INHIBITORS | |
| AR099363A1 (en) | PIRROLO [2,3-D] PIRIMIDINIL, PIRROLO [2,3-B] PIRAZINIL AND PIRROLO [2,3-D] PIRIDINIL ACRYLAMIDS | |
| AR099677A1 (en) | FUSION HETEROCYCLIC COMPOUND AND ITS USE FOR PEST CONTROL | |
| PE20171240A1 (en) | DERIVATIVES OF 4H-PYRROL [3,2-C] PYRIDIN-4-ONA | |
| AR092742A1 (en) | ANTIFIBROTIC PYRIDINONES | |
| AR078609A1 (en) | 8-ETIL-6- (ARIL) PIRIDO [2,3-D] PIRIMIDIN-7 (8H) -ONAS, PHARMACEUTICAL COMPOSITIONS THAT CONTAIN THEM AND USE OF THE SAME FOR THE TREATMENT OF CENTRAL NERVOUS SYSTEMS, SUCH AS DEPRESSION AND CANCERES OF OVARIO AND RENALES, AMONG OTHERS. | |
| AR091193A1 (en) | HETEROCICLES OF 5 MEMBERS CONTAINING NITROGEN REPLACED BY CARBOXAMIDE OR SULFONAMIDE AS MODULATORS FOR THE NURLEAR RECEPTOR HUERFANO RORg | |
| AR099023A1 (en) | PIRAZOLIL-HETEROARILAMIDAS AS PLAGUICIDE AGENTS | |
| AR094550A1 (en) | BTK INHIBITORS | |
| AR101815A1 (en) | COMPOUNDS AND COMPOSITIONS AS QUINASA INHIBITORS | |
| MX2016014197A (en) | 4-PHENYLPIPERIDINS REPLACED, ITS PREPARATION AND USE. | |
| UY37169A (en) | ANALOGS OF 1,4-DIHYDROPIRIMIDIN-5-CARBOXAMIDS AS APJ AGONISTS AND COMPOSITIONS CONTAINING THEM | |
| AR104878A1 (en) | ROR GAMMA MODULATORS (RORg) | |
| AR097866A1 (en) | 4-AZAINDOL DERIVATIVES | |
| AR101479A1 (en) | DERIVATIVES OF 6-ALQUINIL-PIRIDINA | |
| AR103742A1 (en) | DERIVATIVES OF TRIFLUOROMETILPROPANAMIDA | |
| AR107054A1 (en) | DERIVATIVES OF ISOINDOL AND PHARMACEUTICAL COMPOSITIONS THAT INCLUDE THEM FOR THE TREATMENT OF DISEASES MEDIATED BY RORg AND RORgt | |
| AR101255A1 (en) | ISOINDOLINONE DERIVATIVES | |
| AR095040A1 (en) | H3 ANTAGONISTS CONTAINING A STRUCTURAL CORE OF PHENOXIPIPERIDINE | |
| AR100706A1 (en) | NAFTIRIDINADIONA DERIVATIVES | |
| AR104293A1 (en) | INDAZOLONAS AS MODULATORS OF THE TNF SIGNALING |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FB | Suspension of granting procedure |